Balyasny Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Balyasny Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-277,949	Closed	-$5.6M	–	2748
2021 Q3	$5.6M	Buy	277,949 +191,393	+221%	+$5.28M	0.02%	781
2021 Q2	$3.23M	Buy	86,556 +9,476	+12%	+$290K	0.02%	856
2021 Q1	$1.97M	Buy	+77,080	New	+$1.97M	0.01%	1041
2019 Q1	–	Sell	-46,905	Closed	-$501K	–	1753
2018 Q4	$501K	Sell	46,905 -278,595	-86%	-$3.66M	﹤0.01%	1096
2018 Q3	$4.97M	Buy	+325,500	New	+$4.74M	0.02%	700

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Balyasny Asset Management's DRNA Position: Q4 2021 in Review

Balyasny Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 277,949 shares — an estimated $5.6M sold.

Balyasny Asset Management first reported a position in DRNA in Q3 2018 and held it in 5 quarters. The position peaked at $5.6M in Q3 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Balyasny Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Balyasny Asset Management sold 277,949 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $5.6M.
Balyasny Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2018 and held it in 5 quarters.
Balyasny Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $5.6M in Q3 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Balyasny Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.